Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Understanding DKNG – Key Facts Every Investor Should Know

More and more people are talking about DraftKings over the last few weeks. Is it worth buying the Leisure stock at a price of $40.77? Only time will tell. The information below will give you a basic idea of what this investment may entail:

  • DraftKings has moved 8.5% over the last year, and the S&P 500 logged a change of 12.7%

  • DKNG has an average analyst rating of buy and is -22.76% away from its mean target price of $52.78 per share

  • Its trailing earnings per share (EPS) is $-0.82

  • DraftKings has a trailing 12 month Price to Earnings (P/E) ratio of -49.7 while the S&P 500 average is 29.3

  • Its forward earnings per share (EPS) is $0.57 and its forward P/E ratio is 71.5

  • The company has a Price to Book (P/B) ratio of 23.18 in contrast to the S&P 500's average ratio of 4.74

  • DraftKings is part of the Consumer Discretionary sector, which has an average P/E ratio of 20.93 and an average P/B of 2.93

  • The company has a free cash flow of $337.06 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • DraftKings Inc. operates as a digital sports entertainment and gaming company in the United States and internationally. It provides online sports betting, daily fantasy sports, media, digital lottery courier, media, and other products, as well as retails sportsbooks. The company also offers iGaming, or online casino products, which includes blackjack, roulette, baccarat and slot machines. In addition, the company also engages in the design and development of sports betting and casino gaming software for online and retail sportsbooks, and iGaming operators. Further, it offers DraftKings marketplace, a digital collectibles ecosystem designed for mainstream accessibility that offers curated NFT on marketplace. The company is headquartered in Boston, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS